{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:55:54Z","timestamp":1763348154110,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZO1 BC007653"],"award-info":[{"award-number":["ZO1 BC007653"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4.<\/jats:p>","DOI":"10.3390\/toxins10110470","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T10:58:22Z","timestamp":1542193102000},"page":"470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors"],"prefix":"10.3390","volume":"10","author":[{"given":"Yasmin","family":"Leshem","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"},{"name":"Laboratory of Molecular Immunology, Faculty of Biology and Technion Integrated Cancer Center, Technion-Israel Institute of Technology, Haifa 3200003, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-4803","authenticated-orcid":false,"given":"Emily M.","family":"King","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Mazor","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Reiter","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Faculty of Biology and Technion Integrated Cancer Center, Technion-Israel Institute of Technology, Haifa 3200003, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-0270","authenticated-orcid":false,"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u2018Final common pathway\u2019 of human cancer immunotherapy: Targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the pd-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A.Q., Michaud, M., and Mignot, G. (2012). Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med., 4.","DOI":"10.1126\/scitranslmed.3003807"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/am.28.6.987-991.1974","article-title":"Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa","volume":"28","author":"Green","year":"1974","journal-title":"Appl. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","article-title":"Pseudomonas exotoxin A: From virulence factor to anti-cancer agent","volume":"299","author":"Wolf","year":"2009","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted cars: Driving t cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: Ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of ss1p, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hassan, R., Miller, A.C., Sharon, E., Thomas, A., Reynolds, J.C., Ling, A., Kreitman, R.J., Miettinen, M.M., Steinberg, S.M., and Fowler, D.H. (2013). Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3006941"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin rg7787 in pancreatic cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting mesothelin with ctla-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"Il-2 intratumoral immunotherapy enhances cd8+ t cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for il-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor cell death and atp release prime dendritic cells and efficient anticancer immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic t lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of lrp on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-065X.2007.00567.x","article-title":"Ecto-calreticulin in immunogenic chemotherapy","volume":"220","author":"Obeid","year":"2007","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: The calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Risberg, K., Fodstad, O., and Andersson, Y. (2011). Synergistic anticancer effects of the 9.2.27pe immunotoxin and abt-737 in melanoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024012"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1535-7163.MCT-13-0998","article-title":"Abt-737 promotes the dislocation of er luminal proteins to the cytosol, including pseudomonas exotoxin","volume":"13","author":"Antignani","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-80-2-249","article-title":"Adriamycin. A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin ss1p","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-09-0996","article-title":"Interstitial infusion of glioma-targeted recombinant immunotoxin 8h9scfv-pe38","volume":"9","author":"Luther","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00262-007-0363-7","article-title":"Egfrviii-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of cd4+ and cd8+ t cells","volume":"57","author":"Ochiai","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1158\/1078-0432.CCR-06-0192","article-title":"Intratumoral therapy with il13-pe38 results in effective ctl-mediated suppression of Il-13ralpha2-expressing contralateral tumors","volume":"12","author":"Kawakami","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (msln) using different monoclonal antibodies 5b2 and mn-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1215\/S1152851703000589","article-title":"Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin tp-38: Case study","volume":"7","author":"Sampson","year":"2005","journal-title":"Neuro-Oncology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1215\/15228517-2008-012","article-title":"Intracerebral infusion of an egfr-targeted toxin in recurrent malignant brain tumors","volume":"10","author":"Sampson","year":"2008","journal-title":"Neuro-Oncology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02700027","article-title":"Safety, tolerability, and tumor response of il4-pseudomonas exotoxin (nbi-3001) in patients with recurrent malignant glioma","volume":"64","author":"Weber","year":"2003","journal-title":"J. Neuro-Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/B:NEON.0000013478.27604.01","article-title":"Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an il4-targeted toxin (nbi-3001)","volume":"66","author":"Rainov","year":"2004","journal-title":"J. Neuro-Oncol."},{"key":"ref_41","first-page":"105","article-title":"A phase I clinical study of vb4-845: Weekly intratumoral administration of an anti-epcam recombinant fusion protein in patients with squamous cell carcinoma of the head and neck","volume":"2","author":"MacDonald","year":"2009","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/11\/470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:29:37Z","timestamp":1760196577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/11\/470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["toxins10110470"],"URL":"https:\/\/doi.org\/10.3390\/toxins10110470","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2018,11,14]]}}}